secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2025-08-26T23:59:59+00:00
Accession:  0001725160-25-000154
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis appoints James B. Bucher as Chief Legal Officer; Andrea Paul resigns to join law firm
--------------------------------------------------------------------------------

- Andrea Paul resigns as Chief Legal Officer and Corporate Secretary effective Sept 18, 2025.
- James B. Bucher appointed as new Chief Legal Officer and Corporate Secretary effective same date.
- Paul will remain a non-executive employee through Oct 1, 2025, and expects release agreement including 2025 bonus and equity vesting.
- Bucher previously led legal at Harpoon Therapeutics during its Merck acquisition and at Alder Biopharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000154/0001725160-25-000154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000154/zntl-20250826.htm
  HTML page:      https://secwatch.observer/filing/0001725160-25-000154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer